OPTIRAY 350 (ULTRAJECT) 74 % — DIN 02079992
IOVERSOL : 74 % · LIEBEL-FLARSHEIM COMPANY LLC · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is OPTIRAY 350 (ULTRAJECT)?
OPTIRAY 350 (ULTRAJECT) 74 % contains IOVERSOL : 74 %. It is listed in the Health Canada Drug Product Database under DIN 02079992, held by LIEBEL-FLARSHEIM COMPANY LLC, supplied as SOLUTION for INTRAVASCULAR administration. Health Canada currently lists it as dormant, status dated 30-Nov-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is OPTIRAY 350 (ULTRAJECT) used for?
Optiray 350 administered intravascularly is recommended in adults for coronary arteriography and ventriculography, peripheral and visceral arteriography, intravenous contrast enhancement in computed tomography of the head and body, excretory urography, intravenous digital subtraction angiography and venography. Optiray 320 administered intravascularly is recommended for angiography throughout the cardiovascular system in adults. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, aortography and left ventriculography. Optiray 320 is also recommended for contrast enhanced computed tomographic imaging of the head and body and in excretory urography. Optiray 300 administered intravascularly is recommended for use in adults for cerebral angiography, aortography, peripheral and visceral arteriography, intravenous contrast enhancement of computed tomography of the brain and body, excretory urography, intravenous digital subtraction angiography and venography. Optiray 240 administered intravascularly is recommended for use in adults for cerebral angiography, venography, excretory urography as was contrast enhanced computed tomographic imaging of the head and body. Optiray 240 is indicated for subarachnoid administration in adults for lumbar, thoracic, and cervical myelography. In pediatric patients, Optiray 350 administered intravascularly is indicated for angiocardiography, Optiray 320 administered intravascularly is recommended in children one year of age or over for angiocardiography, contrast enhanced computed tomography of the head and body and for excretory urography, and Optiray 300 administered intravascularly is recommended in children one year of age or over for intravenous excretory urography and intra-arterial digital subtraction angiography.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ioversol cost around the world?
Ioversol is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Norway | max AUP (pharmacy retail) | 4 | 41 | NOK███.██ |
| South Africa | single exit price | 15 | 32 | ZAR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 20 | BRL███.██ |
| Hungary | producer price (ex-factory) | 6 | 18 | HUF███.██ |
| Saudi Arabia | public | 6 | 16 | SAR███.██ |
| Czechia | max producer price (ex-factory) | 1 | 15 | CZK███.██ |
| Romania | max producer price | 2 | 6 | RON███.██ |
| Greece | producer price (ex-factory) | 5 | 5 | EUR███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
156 pack listings across 42 brand entries and 8 price bases, refreshed 07 Sep 2026. Ranges span every Ioversol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ioversol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Ioversol, across 11 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| LIEBEL-FLARSHEIM COMPANY LLC | 8 | 0 | OPTIRAY 240, OPTIRAY 240 (ULTRAJECT), OPTIRAY 300, OPTIRAY 300 (ULTRAJECT), OPTIRAY 320, +3 more | No marketed DIN |
| TYCO HEALTHCARE | 2 | 0 | OPTIRAY 160, OPTIRAY 160 (ULTRAJECT) | No marketed DIN |
| MALLINCKRODT CANADA INC. | 1 | 0 | OPTIRAY 240 INJ 240MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 74 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVASCULAR |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Ioversol |
|---|---|
| ATC code | V08AB07 |
| AHFS class | 36:68.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02079992 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2079992 |
| Brand name | OPTIRAY 350 (ULTRAJECT) |
| Generic / active ingredient | IOVERSOL : 74 % |
| Market authorization holder | LIEBEL-FLARSHEIM COMPANY LLC |
| Health Canada schedule | Ethical |
| ATC code | V08AB07 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08AB |
| Current status | DORMANT |
| Status date | 30-Nov-2021 |
| Original market date | 1996-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OPTIRAY 160 | 34 % | SOLUTION | TYCO HEALTHCARE | CANCELLED POST MARKET | 01900838 |
| OPTIRAY 160 (ULTRAJECT) | 34 % | SOLUTION | TYCO HEALTHCARE | CANCELLED PRE MARKET | 02035618 |
| OPTIRAY 240 | 51 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | CANCELLED POST MARKET | 02225263 |
| OPTIRAY 240 (ULTRAJECT) | 51 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | CANCELLED POST MARKET | 02035332 |
| OPTIRAY 240 INJ 240MG/ML | 240 MG | LIQUID | MALLINCKRODT CANADA INC. | CANCELLED POST MARKET | 01900846 |
| OPTIRAY 300 | 64 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | DORMANT | 02034492 |
| OPTIRAY 300 (ULTRAJECT) | 64 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | APPROVED | 02387441 |
| OPTIRAY 320 | 68 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | DORMANT | 01900854 |
| OPTIRAY 320 (ULTRAJECT) | 68 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | DORMANT | 02035626 |
| OPTIRAY 350 | 74 % | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | DORMANT | 02034484 |
2 · Same class — other molecules in ATC V08AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Iopamidol | IOPAMIDOL INJECTION USP · ISOVUE 128 INJ 26% · ISOVUE 128 INJECTION · ISOVUE 200 INJ 41% · +8 more | 15 | 5 | Yes |
| Iodixanol | IODIXANOL INJECTION 270 · IODIXANOL INJECTION 320 · VISIPAQUE 270 · VISIPAQUE 320 | 4 | 4 | Yes |
| Iohexol | OMNIPAQUE 180 · OMNIPAQUE 180 LIQ SAR 388MG/ML · OMNIPAQUE 240 · OMNIPAQUE 240 LIQ IV SAR 518MG/ML · +4 more | 8 | 3 | Yes |
| Iopromide | ULTRAVIST 240 · ULTRAVIST 300 · ULTRAVIST 370 | 3 | 2 | Yes |
| Ioversol | OPTIRAY 160 · OPTIRAY 160 (ULTRAJECT) · OPTIRAY 240 · OPTIRAY 240 (ULTRAJECT) · +7 more | 11 | 0 | Not in Canada |
| Iotrolan | OSMOVIST 240 - LIQ INT 513MG/ML · OSMOVIST 300 - LIQ INT 641MG/ML | 2 | 0 | Not in Canada |
| Ioxaglic Acid | HEXABRIX 200 · HEXABRIX 320 | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V08AA | Diatrizoic Acid · Iotalamic Acid · Ioxitalamic Acid · Watersol., Nephrotropic, High Osm. X-Ray Contr. Media | 41 | 1 |
| V08AD | Ethyl Esters Of Iodised Fatty Acids · Iopydol | 2 | 1 |
| V08AC | Adipiodone · Iopanoic Acid · Sodium Iopodate | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OPTIRAY 350 (ULTRAJECT) called?
The same molecule, Ioversol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Optiray | Latin | Brazil, Czechia, Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.